Difference between revisions of "Carboplatin, Pemetrexed, Pembrolizumab in advanced or metastatic non-small cell lung cancer"

Revision as of 00:45, 12 May 2017

Study	Evidence	Comparator	Efficacy
Langer et al. 2016 (KEYNOTE-021)	Randomized Phase II	Carboplatin & Pemetrexed +/- pemetrexed maintenance	Superior ORR

Carboplatin (Paraplatin) AUC 5 IV over 15 to 60 minutes once on day 1
Pemetrexed (Alimta) 500 mg/m² IV over 10 minutes once on day 1
Pembrolizumab (Keytruda) 200 mg IV over 30 minutes once on day 1, given at least 30 minutes prior to chemotherapy

"Premedication with folic acid, vitamin B12, and corticosteroids was administered according to local guidelines."

Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators.. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497-1508 link to original article contains verified protocol supplementary appendix; PubMed

@@ Line 32: / Line 32: @@
 *[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1
 *[[Pembrolizumab (Keytruda)]] 200 mg IV over 30 minutes once on day 1, '''given at least 30 minutes prior to chemotherapy'''
+====Supportive medications====
+*"Premedication with folic acid, vitamin B12, and corticosteroids was administered according to local guidelines."
 '''21-day cycle for 4 cycles.''' Followed by [[Pembrolizumab (Keytruda) maintenance therapy for advanced or metastatic non-small cell lung cancer|pembolizumab maintenance therapy]] and optional [[Pemetrexed (Alimta) maintenance therapy for advanced or metastatic non-small cell lung cancer|pemetrexed maintenance therapy]]